8-K: VBI Vaccines Expands Canadian Government Partnership to Advance Novel mRNA Vaccine Platform

VBI Vaccines has expanded its collaboration with the Canadian government, securing CAD$28 million in funding to advance its mRNA-launched enveloped virus-like particle (MLE) vaccine technology.

Summary

• VBI Vaccines has broadened its partnership with the Canadian government to further develop its novel mRNA-launched enveloped virus-like particle (MLE) vaccine platform.
• The collaboration will utilize the remaining CAD$28 million from an original CAD$56 million award to advance the MLE technology.
• The MLE platform is a next-generation version of VBI's enveloped virus-like particle (eVLP) technology, using mRNA to code for eVLPs.
• Preclinical studies of VBI's MLE candidates have shown strong B-cell and T-cell responses compared to other mRNA vaccines.
• The MLE technology also offers the potential for faster manufacturing timelines, similar to other mRNA vaccines.
• The partnership will also support the development of stable cell lines and the optimization of manufacturing processes.
• The primary focus of the development will be on the platform itself, including a pan-coronavirus MLE candidate for future pandemic preparedness.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the increased funding, promising technology, and potential for future growth. The expansion of the Canadian government partnership is a strong positive signal.

Positives

• The expanded partnership with the Canadian government provides significant funding for VBI's MLE platform development.
• The MLE technology has shown promising preclinical results with strong immune responses.
• The MLE platform has the potential for faster manufacturing timelines, which is a key advantage.
• The collaboration includes support for developing stable cell lines and optimizing manufacturing processes.
• The development includes a pan-coronavirus MLE candidate, which is important for future pandemic preparedness.

Risks

• The company's ability to regain and maintain compliance with the listing standards of the Nasdaq Capital Market is a risk.
• The company's ability to satisfy all of the conditions to the consummation of the transactions with Brii Biosciences is a risk.
• The company's ability to comply with its obligations under its loan agreement with K2 HealthVentures is a risk.
• The impact of general economic, industry or political conditions in the United States or internationally could affect the company.
• The impact and continuing effects of the COVID-19 endemic on clinical studies, manufacturing, business plan, and the global economy is a risk.
• The ability to successfully manufacture and commercialize PreHevbrio/PreHevbri is a risk.
• The ability to establish that potential products are efficacious or safe in preclinical or clinical trials is a risk.
• The ability to establish or maintain collaborations on the development of pipeline candidates and the commercialization of PreHevbrio/PreHevbri is a risk.
• The ability to obtain appropriate or necessary regulatory approvals to market potential products is a risk.
• The ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms is a risk.
• The company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties is a risk.
• Changes in the size and nature of competitors is a risk.
• The ability to retain key executives and scientists is a risk.
• The ability to secure and enforce legal rights related to the company's products is a risk.

Future Outlook

The company will use the funding to validate and expand the MLE technology, which they believe has broad applicability. They will also focus on developing stable cell lines and optimizing manufacturing processes. The development will include a pan-coronavirus MLE candidate to contribute toward future epidemic and pandemic preparedness.

Management Comments

• Jeff Baxter, President and CEO of VBI, stated that they are grateful for the continued support of the Canadian government.
• Jeff Baxter believes the MLE platform has the potential to revolutionize particulate vaccines.

Industry Context

This announcement highlights the ongoing interest and investment in mRNA vaccine technology, particularly in the development of next-generation platforms that offer improved efficacy and manufacturing capabilities. The focus on a pan-coronavirus candidate also reflects the industry's continued efforts to prepare for future pandemics.

Comparison to Industry Standards

• The development of mRNA-launched eVLP technology is a novel approach compared to standard mRNA vaccines, which typically use lipid nanoparticles for delivery.
• The reported strong B-cell and T-cell responses in preclinical studies are promising and could potentially surpass the efficacy of some existing mRNA vaccines.
• The focus on streamlined manufacturing timelines aligns with the industry's push for faster and more efficient vaccine production.
• Companies like Moderna and BioNTech have pioneered mRNA vaccine technology, but VBI's approach with eVLPs could offer a differentiated advantage.

Stakeholder Impact

• Shareholders may view this announcement positively due to the increased funding and potential for future growth.
• Employees may be positively impacted by the expansion of research and development efforts.
• The development of a pan-coronavirus vaccine could benefit the broader public by contributing to pandemic preparedness.

Next Steps

• VBI will use the funding to validate and expand the MLE technology.
• The company will develop stable cell lines and optimize manufacturing processes.
• The company will continue development of a pan-coronavirus MLE candidate.

Key Dates

Keywords

mRNA vaccine, eVLP, MLE, VBI Vaccines, Canadian government, Strategic Innovation Fund, vaccine technology, immunology, biopharmaceutical, pandemic preparedness